Search

Your search keyword '"Weekes, Colin D."' showing total 351 results
Start Over Author "Weekes, Colin D."
351 results on '"Weekes, Colin D."'

1. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Author

Pant, Shubham, Wainberg, Zev A., Weekes, Colin D., Furqan, Muhammad, Kasi, Pashtoon M., Devoe, Craig E., Leal, Alexis D., Chung, Vincent, Basturk, Olca, VanWyk, Haley, Tavares, Amy M., Seenappa, Lochana M., Perry, James R., Kheoh, Thian, McNeil, Lisa K., Welkowsky, Esther, DeMuth, Peter C., Haqq, Christopher M., and O’Reilly, Eileen M.

Published
2024
Full Text
View/download PDF

3. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma

Author

Qiao, Guoliang, Fong, Zhi Ven, Bolm, Louisa, Fernandez del-Castillo, Carlos, Ferrone, Cristina R., Servin-Rojas, Maximiliano, Pathak, Priyadarshini, Lau-Min, Kelsey, Allen, Jill N., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Parikh, Aparna R., Ryan, David P., Weekes, Colin D., Roberts, Hannah M., Wo, Jennifer Y., Hong, Theodore S., Lillemoe, Keith D., and Qadan, Motaz

Published
2024
Full Text
View/download PDF

4. Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience

Author

Gupta, Arjun, Khalid, Omar, Moravek, Cassadie, Lamkin, Anica, Matrisian, Lynn M, Doss, Sudheer, Denlinger, Crystal S, Coveler, Andrew L, Weekes, Colin D, Roeland, Eric J, Hendifar, Andrew E, and Nipp, Ryan D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Pancreatic Cancer, Cancer, Prevention, Digestive Diseases, Management of diseases and conditions, 7.1 Individual care needs, Adult, Advertising, Aged, Aged, 80 and over, Cancer Care Facilities, Feasibility Studies, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Patient Participation, Patient Reported Outcome Measures, Precision Medicine, Registries, Research, United States, Young Adult, PanCAN, pancreatic cancer, patient-reported outcomes, registry, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundThe Pancreatic Cancer Action Network (PanCAN) Patient Registry is an online, pancreatic cancer-specific, global registry enabling patients to self-report sociodemographics, disease/management characteristics, and patient-reported outcomes (PROs). We sought to describe the creation, user experience, and research potential of the PanCAN Registry.MethodsWe obtained data to describe (1) the creation of the Registry (questionnaire development, marketing efforts, and regulatory considerations); (2) the user experience (user characteristics and interactions with the registry following inception); and (3) the research potential of the registry (comparing PROs and treatment patterns by age [±65 years] and treatment site [community or academic] for users with de novo metastatic disease).ResultsThe Registry was conceived as part of PanCAN's strategic plan for a personalized therapy initiative. PanCAN staff and disease expert consultants developed questionnaires hosted on an electronic PRO platform. Users had the option to include their data in research efforts, and the Registry platform received institutional review board approval. From 7/2015 to 12/2020, 2187 patients visited the registry and 1697 (77.6%) completed at least one survey (median age = 64 years [range: 24-90], 47.9% women, 88.7% White, 34.0% metastatic disease). Among patients with metastatic disease (N = 567), 46.0% were ≥65 years old and 67.5% received treatment at community sites. Patients ≥65 years reported feeling less hopeful about the treatment plan (12.4% vs. 24.3%, p = 0.003), and patients treated at community sites reported more frequent treatment breaks of >2 weeks (58.2% vs. 28.1%, p

Published
2021

5. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients with Pancreatic Ductal Adenocarcinoma

Author

Qiao, Guoliang, Fong, Zhi Ven, Bolm, Louisa, Fernandez del-Castillo, Carlos, Ferrone, Cristina R, Servin-Rojas, Maximiliano, Pathak, Priyadarshini, Lau-Min, Kelsey, Allen, Jill N, Blaszkowsky, Lawrence S, Clark, Jeffrey W, Parikh, Aparna R, Ryan, David P, Weekes, Colin D, Roberts, Hannah M, Wo, Jennifer Y, Hong, Theodore S, Lillemoe, Keith D, and Qadan, Motaz

Published
2023
Full Text
View/download PDF

6. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

Author

Hwang, William L., Jagadeesh, Karthik A., Guo, Jimmy A., Hoffman, Hannah I., Yadollahpour, Payman, Reeves, Jason W., Mohan, Rahul, Drokhlyansky, Eugene, Van Wittenberghe, Nicholas, Ashenberg, Orr, Farhi, Samouil L., Schapiro, Denis, Divakar, Prajan, Miller, Eric, Zollinger, Daniel R., Eng, George, Schenkel, Jason M., Su, Jennifer, Shiau, Carina, Yu, Patrick, Freed-Pastor, William A., Abbondanza, Domenic, Mehta, Arnav, Gould, Joshua, Lambden, Conner, Porter, Caroline B. M., Tsankov, Alexander, Dionne, Danielle, Waldman, Julia, Cuoco, Michael S., Nguyen, Lan, Delorey, Toni, Phillips, Devan, Barth, Jaimie L., Kem, Marina, Rodrigues, Clifton, Ciprani, Debora, Roldan, Jorge, Zelga, Piotr, Jorgji, Vjola, Chen, Jonathan H., Ely, Zackery, Zhao, Daniel, Fuhrman, Kit, Fropf, Robin, Beechem, Joseph M., Loeffler, Jay S., Ryan, David P., Weekes, Colin D., Ferrone, Cristina R., Qadan, Motaz, Aryee, Martin J., Jain, Rakesh K., Neuberg, Donna S., Wo, Jennifer Y., Hong, Theodore S., Xavier, Ramnik, Aguirre, Andrew J., Rozenblatt-Rosen, Orit, Mino-Kenudson, Mari, Castillo, Carlos Fernandez-del, Liss, Andrew S., Ting, David T., Jacks, Tyler, and Regev, Aviv

Published
2022
Full Text
View/download PDF

7. Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis

Author

Furtado, Felipe S., Wu, Mark Z., Esfahani, Shadi A., Ferrone, Cristina R., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Ryan, David P., Goyal, Lipika, Franses, Joseph W., Wo, Jennifer Y., Hong, Theodore S., Qadan, Motaz, Tanabe, Kenneth K., Weekes, Colin D., Cusack, James C., Crafa, Francesco, Mahmood, Umar, Anderson, Mark A., Mojtahed, Amirkasra, Hahn, Peter F., Caravan, Peter, Kilcoyne, Aoife, Vangel, Mark, Striar, Robin M., Rosen, Bruce R., and Catalano, Onofrio A.

Published
2023
Full Text
View/download PDF

8. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

Author

Strickler, John H, Weekes, Colin D, Nemunaitis, John, Ramanathan, Ramesh K, Heist, Rebecca S, Morgensztern, Daniel, Angevin, Eric, Bauer, Todd M, Yue, Huibin, Motwani, Monica, Parikh, Apurvasena, Reilly, Edward B, Afar, Daniel, Naumovski, Louie, and Kelly, Karen

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prevention, Lung Cancer, Immunization, Lung, Clinical Research, Clinical Trials and Supportive Activities, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms, Proto-Oncogene Proteins c-met, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThis first-in-human study evaluated telisotuzumab vedotin (Teliso-V), formerly called ABBV-399, an antibody-drug conjugate of the anti-c-Met monoclonal antibody ABT-700 and monomethyl auristatin E.Materials and methodsFor dose escalation, three to six patients with advanced solid tumors were enrolled in eight cohorts (0.15 to 3.3 mg/kg). The dose-expansion phase enrolled patients with non-small-cell lung cancer (NSCLC) with c-Met-overexpressing tumors (c-Met positive; immunohistochemistry membrane H-score ≥ 150). Patients received Teliso-V monotherapy intravenously on day 1 once every 3 weeks. Safety, tolerability, pharmacokinetics, and maximum tolerated dose were determined.ResultsForty-eight patients were enrolled (median age, 65 years; 35.4% NSCLC; median four prior therapies). One patient each in the 3.0-mg/kg (n = 9) and 3.3-mg/kg (n = 3) cohorts experienced dose-limiting toxicities. Although the maximum tolerated dose was not formally identified, the recommended phase II dose was defined as 2.7 mg/kg on the basis of overall safety and tolerability. The most frequent treatment-emergent adverse events (any grade) were fatigue (42%), nausea (27%), constipation (27%), decreased appetite (23%), vomiting (21%), dyspnea (21%), diarrhea (19%), peripheral edema (19%), and neuropathy (17%). The most frequent Teliso-V-related grade ≥ 3 adverse events were fatigue, anemia, neutropenia, and hypoalbuminemia (4% each). Teliso-V and total antibody pharmacokinetics were approximately dose proportional, with a mean harmonic half-life of 2 to 4 days each. Prospective screening identified 35 (60%) of 58 patients with c-Met-positive NSCLC. Of 16 patients with c-Met-positive NSCLC who were treated with Teliso-V 2.4 to 3.0 mg/kg, three (18.8%; 95% CI, 4.1% to 45.7%) achieved a partial response (median response duration, 4.8 months; median progression-free survival, 5.7 months; 95% CI, 1.2 months to 15.4 months). No other patients experienced a response.ConclusionTeliso-V monotherapy demonstrated favorable safety and tolerability profiles, with encouraging evidence of antitumor activity in patients with c-Met-positive NSCLC.

Published
2018

10. Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Author

Corcoran, Ryan B., primary, Do, Khanh T., primary, Kim, Jeong E., primary, Cleary, James M., primary, Parikh, Aparna R., primary, Yeku, Oladapo O., primary, Xiong, Niya, primary, Weekes, Colin D., primary, Veneris, Jennifer, primary, Ahronian, Leanne G., primary, Mauri, Gianluca, primary, Tian, Jun, primary, Norden, Bryanna L., primary, Michel, Alexa G., primary, Van Seventer, Emily E., primary, Siravegna, Giulia, primary, Camphausen, Kyle, primary, Chi, Gary, primary, Fetter, Isobel J., primary, Brugge, Joan S., primary, Chen, Helen, primary, Takebe, Naoko, primary, Penson, Richard T., primary, Juric, Dejan, primary, Flaherty, Keith T., primary, Sullivan, Ryan J., primary, Clark, Jeffrey W., primary, Heist, Rebecca S., primary, Matulonis, Ursula A., primary, Liu, Joyce F., primary, and Shapiro, Geoffrey I., primary

Published
2024
Full Text
View/download PDF

11. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy

Author

Michelakos, Theodoros, Sekigami, Yurie, Kontos, Filippos, Fernández-del Castillo, Carlos, Qadan, Motaz, Deshpande, Vikram, Ting, David T., Clark, Jeffrey W., Weekes, Colin D., Parikh, Aparna, Ryan, David P., Wo, Jennifer Y., Hong, Theodore S., Allen, Jill N., Catalano, Onofrio, Warshaw, Andrew L., Lillemoe, Keith D., and Ferrone, Cristina R.

Published
2021
Full Text
View/download PDF

12. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial

Author

Parikh, Aparna R., Szabolcs, Annamaria, Allen, Jill N., Clark, Jeffrey W., Wo, Jennifer Y., Raabe, Michael, Thel, Hannah, Hoyos, David, Mehta, Arnav, Arshad, Sanya, Lieb, David J., Drapek, Lorraine C., Blaszkowsky, Lawrence S., Giantonio, Bruce J., Weekes, Colin D., Zhu, Andrew X., Goyal, Lipika, Nipp, Ryan D., Dubois, Jon S., Van Seventer, Emily E., Foreman, Bronwen E., Matlack, Lauren E., Ly, Leilana, Meurer, Jessica A., Hacohen, Nir, Ryan, David P., Yeap, Beow Y., Corcoran, Ryan B., Greenbaum, Benjamin D., Ting, David T., and Hong, Theodore S.

Published
2021
Full Text
View/download PDF

13. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Author

Bendell, Johanna C, Javle, Milind, Bekaii-Saab, Tanios S, Finn, Richard S, Wainberg, Zev A, Laheru, Daniel A, Weekes, Colin D, Tan, Benjamin R, Khan, Gazala N, Zalupski, Mark M, Infante, Jeffrey R, Jones, Suzanne, Papadopoulos, Kyriakos P, Tolcher, Anthony W, Chavira, Renae E, Christy-Bittel, Janna L, Barrett, Emma, and Patnaik, Amita

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Digestive Diseases, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Benzimidazoles, Drug Administration Schedule, Female, Humans, MAP Kinase Kinase 1, MAP Kinase Kinase 2, Male, Maximum Tolerated Dose, Neoplasms, Proto-Oncogene Proteins B-raf, Treatment Outcome, ras Proteins, binimetinib, MEK162, MEK inhibitor, gastrointestinal cancers, colorectal cancers, clinical trial, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundBinimetinib (MEK162; ARRY-438162) is a potent and selective oral MEK 1/2 inhibitor. This phase 1 study determined the maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and preliminary anti-tumour activity of binimetinib in patients with advanced solid tumours, with expansion cohorts of patients with biliary cancer or KRAS- or BRAF-mutant colorectal cancer.MethodsBinimetinib was administered twice daily. Expansion cohorts were enroled after MTD determination following a 3+3 dose-escalation design. Pharmacokinetic properties were determined from plasma samples. Tumour samples were assessed for mutations in RAS, RAF, and other relevant genes. Pharmacodynamic properties were evaluated in serum and skin punch biopsy samples.ResultsNinety-three patients received binimetinib (dose-escalation phase, 19; expansion, 74). The MTD was 60 mg twice daily, with dose-limiting adverse events (AEs) of dermatitis acneiform and chorioretinopathy. The dose for expansion patients was subsequently decreased to 45 mg twice daily because of the frequency of treatment-related ocular toxicity at the MTD. Common AEs across all dose levels included rash (81%), nausea (56%), vomiting (52%), diarrhoea (51%), peripheral oedema (46%), and fatigue (43%); most were grade 1/2. Dose-proportional increases in binimetinib exposure were observed and target inhibition was demonstrated in serum and skin punch biopsy samples. Three patients with biliary cancer had objective responses (one complete and two partial).ConclusionsBinimetinib demonstrated a manageable safety profile, target inhibition, and dose-proportional exposure. The 45 mg twice daily dose was identified as the recommended phase 2 dose. The three objective responses in biliary cancer patients are encouraging and support further evaluation in this population.

Published
2017

16. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer

Author

Nipp, Ryan D., Gaufberg, Eva, Vyas, Charu, Azoba, Chinenye, Qian, Carolyn L., Jaggers, Jordon, Weekes, Colin D., Allen, Jill N., Roeland, Eric J., Parikh, Aparna R., Miller, Laurie, Wo, Jennifer Y., Smith, Melissa Hennessey, Brown, Patricia M.C., Shulman, Eliza, Fernandez-del Castillo, Carlos, Kimmelman, Alec C., Ting, David, Hong, Theodore S., Greer, Joseph A., Ryan, David P., Temel, Jennifer S., and El-Jawahri, Areej

Published
2022
Full Text
View/download PDF

17. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma.

Author

Guoliang Qiao, Zhi Ven Fong, Bolm, Louisa, Fernandez del-Castillo, Carlos, Ferrone, Cristina R., Servin-Rojas, Maximiliano, Pathak, Priyadarshini, Lau-Min, Kelsey, Allen, Jill N., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Parikh, Aparna R., Ryan, David P., Weekes, Colin D., Roberts, Hannah M., Wo, Jennifer Y., Hong, Theodore S., Lillemoe, Keith D., and Qadan, Motaz

Abstract

Objective: To evaluate the safety and efficacy of neoadjuvant therapy (NAT), followed by surgical resection in patients with pancreatic ductal adenocarcinoma (PDAC) aged ≥75 years. Background: Whether administration of NAT, followed by surgical resection in elderly patients with PDAC is safe and effective is unknown. Methods: The present study is a three-part comparison of older (≥ 75 years) versus younger (< 75 years) patients in different settings throughout the continuum of PDAC care. The first analysis was a comparison of older versus younger consecutive patients with nonmetastatic PDAC who were initiated on FOLFIRINOX. The second was a comparison of older versus younger patients who underwent NAT, followed by surgical resection, and the third and final analysis was a comparison of older patients who underwent either NAT, followed by surgical resection versus upfront surgical resection. Postoperative complications, overall survival (OS), and time to recurrence (TTR) were compared. Propensity score matching (PSM) analysis was performed to adjust for potential confounders. Results: In the first analysis, a lower proportion of older patients (n = 40) were able to complete the intended neoadjuvant FOLFIRINOX (8) cycles compared with younger patients (n = 214; 65.0% vs 81.4%, P = 0.021). However, older patients were just as likely to undergo surgical exploration as younger patients (77.5% vs 78.5%, P = 0.89), as well as surgical resection (57.5% vs 55.6%, P = 0.70). In the second analysis, PSM was conducted to compare older (n = 54) versus younger patients (n = 54) who underwent NAT, followed by surgical resection. There were no significant differences in postoperative complications between the matched groups. While there was a significant difference in OS between older and younger patients (median OS: 16.43 vs 30.83 months, P = 0.002), importantly, there was no significant difference in TTR (median: 7.65 vs 11.83 months, P = 0.215). In the third analysis, older patients who underwent NAT, followed by surgical resection (n = 48) were compared with similar older patients who underwent upfront surgical resection (n = 48). After PSM, there was a significant difference in OS (median OS: 15.78 months vs 11.51 months, P = 0.037), as well as TTR (median TTR: 8.81 vs 7.10 months, P = 0.046) representing an association with improved outcomes that favored the neoadjuvant approach among older patients alone. Conclusions: This comprehensive three-part study showed that administration of NAT, followed by surgical resection, seems to be safe and effective among patients ≥75 years of age. An aggressive approach should be offered to older adults undergoing multimodal treatment of PDAC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Positron Emission Tomography/Magnetic Resonance Imaging Versus the Standard of Care Imaging in the Diagnosis of Peritoneal Carcinomatosis

Author

Furtado, Felipe S., Wu, Mark Z., Esfahani, Shadi A., Ferrone, Cristina R., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Ryan, David P., Goyal, Lipika, Franses, Joseph W., Wo, Jennifer Y., Hong, Theodore S., Qadan, Motaz, Tanabe, Kenneth K., Weekes, Colin D., Cusack, James C., Crafa, Francesco, Mahmood, Umar, Anderson, Mark A., Mojtahed, Amirkasra, Hahn, Peter F., Caravan, Peter, Kilcoyne, Aoife, Vangel, Mark, Striar, Robin R., Rosen, Bruce R., and Catalano, Onofrio A.

Published
2022
Full Text
View/download PDF

20. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Author

Corcoran, Ryan B., primary, Do, Khanh T., additional, Kim, Jeong E., additional, Cleary, James M., additional, Parikh, Aparna R., additional, Yeku, Oladapo O., additional, Xiong, Niya, additional, Weekes, Colin D., additional, Veneris, Jennifer, additional, Ahronian, Leanne G., additional, Mauri, Gianluca, additional, Tian, Jun, additional, Norden, Bryanna L., additional, Michel, Alexa G., additional, Van Seventer, Emily E., additional, Siravegna, Giulia, additional, Camphausen, Kyle, additional, Chi, Gary, additional, Fetter, Isobel J., additional, Brugge, Joan S., additional, Chen, Helen, additional, Takebe, Naoko, additional, Penson, Richard T., additional, Juric, Dejan, additional, Flaherty, Keith T., additional, Sullivan, Ryan J., additional, Clark, Jeffrey W., additional, Heist, Rebecca S., additional, Matulonis, Ursula A., additional, Liu, Joyce F., additional, and Shapiro, Geoffrey I., additional

Published
2024
Full Text
View/download PDF

21. Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine

Author

Wainberg, Zev A., primary, Pant, Shubham, additional, Weekes, Colin D., additional, Furqan, Muhammad, additional, Kasi, Pashtoon M., additional, Devoe, Craig E., additional, Leal, Alexis D., additional, Chung, Vincent, additional, Perry, James R., additional, Seenappa, Lochana, additional, McNeil, Lisa K., additional, Welkowsky, Esther, additional, DeMuth, Peter C., additional, Haqq, Christopher M., additional, and O'Reilly, Eileen M., additional

Published
2024
Full Text
View/download PDF

22. Care Patterns and Overall Survival in Patients With Early-Onset Metastatic Colorectal Cancer

Author

Kanter, Katie, Fish, Madeleine, Mauri, Gianluca, Horick, Nora K., Allen, Jill N., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Ryan, David P., Nipp, Ryan D., Giantonio, Bruce J., Goyal, Lipika, Dubois, Jon, Murphy, Janet E., Franses, Joseph, Klempner, Samuel J., Roeland, Eric J., Weekes, Colin D., Wo, Jennifer Y., Hong, Theodore S., Van Seventer, Emily E., Corcoran, Ryan B., and Parikh, Aparna R.

Published
2021
Full Text
View/download PDF

23. Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer

Author

Jarnagin, Joy X., primary, Saraf, Anurag, additional, Baiev, Islam, additional, Chi, Gary, additional, van Seventer, Emily E., additional, Mojtahed, Amirkasra, additional, Allen, Jill N., additional, Clark, Jeffrey W., additional, Blaszkowsky, Lawrence, additional, Giantonio, Bruce J., additional, Weekes, Colin D., additional, Klempner, Samuel J., additional, Franses, Joseph W., additional, Roeland, Eric J., additional, Goyal, Lipika, additional, Siravegna, Giulia, additional, Horick, Nora, additional, Corcoran, Ryan B., additional, Nipp, Ryan D., additional, and Parikh, Aparna R., additional

Published
2023
Full Text
View/download PDF

24. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer

Author

McDuff, Susan G. R., Hardiman, Karin M., Ulintz, Peter J., Parikh, Aparna R., Zheng, Hui, Kim, Daniel W., Lennerz, Jochen K., Hazar-Rethinam, Mehlika, Van Seventer, Emily E., Fetter, Isobel J., Nadres, Brandon, Eyler, Christine E., Ryan, David P., Weekes, Colin D., Clark, Jeffrey W., Cusack, James C., Goyal, Lipika, Zhu, Andrew X., Wo, Jennifer Y., Blaszkowsky, Lawrence S., Allen, Jill, Corcoran, Ryan B., and Hong, Theodore S.

Published
2021
Full Text
View/download PDF

28. Supplementary Table S2 from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Author

Parikh, Aparna R., primary, Mojtahed, Amikasra, primary, Schneider, Jaime L., primary, Kanter, Katie, primary, Van Seventer, Emily E., primary, Fetter, Isobel J., primary, Thabet, Ashraf, primary, Fish, Madeleine G., primary, Teshome, Bezaye, primary, Fosbenner, Kathryn, primary, Nadres, Brandon, primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Ryan, David P., primary, Giantonio, Bruce, primary, Goyal, Lipika, primary, Nipp, Ryan D., primary, Roeland, Eric, primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Zhu, Andrew X., primary, Dias-Santagata, Dora, primary, Iafrate, A. John, primary, Lennerz, Jochen K., primary, Hong, Theodore S., primary, Siravegna, Giulia, primary, Horick, Nora, primary, Clark, Jeffrey W., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Methods, Figure 1,Tables 1-6 from Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Author

Bowles, Daniel W., primary, Diamond, Jennifer R., primary, Lam, Elaine T., primary, Weekes, Colin D., primary, Astling, David P., primary, Anderson, Ryan T., primary, Leong, Stephen, primary, Gore, Lia, primary, Varella-Garcia, Marileila, primary, Vogler, Brian W., primary, Keysar, Stephen B., primary, Freas, Elizabeth, primary, Aisner, Dara L., primary, Ren, Chen, primary, Tan, Aik-Chook, primary, Wilhelm, Francois, primary, Maniar, Manoj, primary, Eckhardt, S. Gail, primary, Messersmith, Wells A., primary, and Jimeno, Antonio, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Author

Ma, Wen Wee, primary, Messersmith, Wells A., primary, Dy, Grace K., primary, Weekes, Colin D., primary, Whitworth, Amy, primary, Ren, Chen, primary, Maniar, Manoj, primary, Wilhelm, Francois, primary, Eckhardt, S. Gail, primary, Adjei, Alex A., primary, and Jimeno, Antonio, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Tables 1-3 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S1 from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure 4 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Author

Xin, Yan, primary, Li, Jessica, primary, Wu, Jenny, primary, Kinard, Rashell, primary, Weekes, Colin D., primary, Patnaik, Amita, primary, LoRusso, Patricia, primary, Brachmann, Rainer, primary, Tong, Raymond K., primary, Yan, Yibing, primary, Watts, Ryan, primary, Bai, Shuang, primary, and Hegde, Priti S., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure Legend from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Data from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Author

Parikh, Aparna R., primary, Mojtahed, Amikasra, primary, Schneider, Jaime L., primary, Kanter, Katie, primary, Van Seventer, Emily E., primary, Fetter, Isobel J., primary, Thabet, Ashraf, primary, Fish, Madeleine G., primary, Teshome, Bezaye, primary, Fosbenner, Kathryn, primary, Nadres, Brandon, primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Ryan, David P., primary, Giantonio, Bruce, primary, Goyal, Lipika, primary, Nipp, Ryan D., primary, Roeland, Eric, primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Zhu, Andrew X., primary, Dias-Santagata, Dora, primary, Iafrate, A. John, primary, Lennerz, Jochen K., primary, Hong, Theodore S., primary, Siravegna, Giulia, primary, Horick, Nora, primary, Clark, Jeffrey W., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

36. Data from Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Author

Parikh, Aparna R., primary, Van Seventer, Emily E., primary, Siravegna, Giulia, primary, Hartwig, Anna V., primary, Jaimovich, Ariel, primary, He, Yupeng, primary, Kanter, Katie, primary, Fish, Madeleine G., primary, Fosbenner, Kathryn D., primary, Miao, Benchun, primary, Phillips, Susannah, primary, Carmichael, John H., primary, Sharma, Nihaarika, primary, Jarnagin, Joy, primary, Baiev, Islam, primary, Shah, Yojan S., primary, Fetter, Isobel J., primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Clark, Jeffrey W., primary, Dubois, Jon S., primary, Franses, Joseph W., primary, Giantonio, Bruce J., primary, Goyal, Lipika, primary, Klempner, Samuel J., primary, Nipp, Ryan D., primary, Roeland, Eric J., primary, Ryan, David P., primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Hong, Theodore S., primary, Bordeianou, Liliana, primary, Ferrone, Cristina R., primary, Qadan, Motaz, primary, Kunitake, Hiroko, primary, Berger, David, primary, Ricciardi, Rocco, primary, Cusack, James C., primary, Raymond, Victoria M., primary, Talasaz, AmirAli, primary, Boland, Genevieve M., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Methods from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

Author

Parikh, Aparna R., primary, Mojtahed, Amikasra, primary, Schneider, Jaime L., primary, Kanter, Katie, primary, Van Seventer, Emily E., primary, Fetter, Isobel J., primary, Thabet, Ashraf, primary, Fish, Madeleine G., primary, Teshome, Bezaye, primary, Fosbenner, Kathryn, primary, Nadres, Brandon, primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Ryan, David P., primary, Giantonio, Bruce, primary, Goyal, Lipika, primary, Nipp, Ryan D., primary, Roeland, Eric, primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Zhu, Andrew X., primary, Dias-Santagata, Dora, primary, Iafrate, A. John, primary, Lennerz, Jochen K., primary, Hong, Theodore S., primary, Siravegna, Giulia, primary, Horick, Nora, primary, Clark, Jeffrey W., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Data from A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors

Author

Tolaney, Sara M., primary, Do, Khanh T., primary, Eder, Joseph P., primary, LoRusso, Patricia M., primary, Weekes, Colin D., primary, Chandarlapaty, Sarat, primary, Chang, Ching-Wei, primary, Chen, Shang-Chiung, primary, Nazzal, Denise, primary, Schuth, Eva, primary, Brunstein, Flavia, primary, Carrasco-Triguero, Montserrat, primary, Darbonne, Walter C., primary, Giltnane, Jennifer M., primary, Flanagan, William M., primary, Commerford, S. Renee, primary, Ungewickell, Alexander, primary, Shapiro, Geoffrey I., primary, and Modi, Shanu, primary

Published
2023
Full Text
View/download PDF

39. Data from Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Author

Weekes, Colin D., primary, Von Hoff, Daniel D., primary, Adjei, Alex A., primary, Leffingwell, Diane P., primary, Eckhardt, S. Gail, primary, Gore, Lia, primary, Lewis, Karl D., primary, Weiss, Glen J., primary, Ramanathan, Ramesh K., primary, Dy, Grace K., primary, Ma, Wen W., primary, Sheedy, Beth, primary, Iverson, Cory, primary, Miner, Jeffrey N., primary, Shen, Zancong, primary, Yeh, Li-Tain, primary, Dubowy, Ronald L., primary, Jeffers, Michael, primary, Rajagopalan, Prabhu, primary, and Clendeninn, Neil J., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Tables from Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Author

Parikh, Aparna R., primary, Van Seventer, Emily E., primary, Siravegna, Giulia, primary, Hartwig, Anna V., primary, Jaimovich, Ariel, primary, He, Yupeng, primary, Kanter, Katie, primary, Fish, Madeleine G., primary, Fosbenner, Kathryn D., primary, Miao, Benchun, primary, Phillips, Susannah, primary, Carmichael, John H., primary, Sharma, Nihaarika, primary, Jarnagin, Joy, primary, Baiev, Islam, primary, Shah, Yojan S., primary, Fetter, Isobel J., primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Clark, Jeffrey W., primary, Dubois, Jon S., primary, Franses, Joseph W., primary, Giantonio, Bruce J., primary, Goyal, Lipika, primary, Klempner, Samuel J., primary, Nipp, Ryan D., primary, Roeland, Eric J., primary, Ryan, David P., primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Hong, Theodore S., primary, Bordeianou, Liliana, primary, Ferrone, Cristina R., primary, Qadan, Motaz, primary, Kunitake, Hiroko, primary, Berger, David, primary, Ricciardi, Rocco, primary, Cusack, James C., primary, Raymond, Victoria M., primary, Talasaz, AmirAli, primary, Boland, Genevieve M., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Author

Xin, Yan, primary, Li, Jessica, primary, Wu, Jenny, primary, Kinard, Rashell, primary, Weekes, Colin D., primary, Patnaik, Amita, primary, LoRusso, Patricia, primary, Brachmann, Rainer, primary, Tong, Raymond K., primary, Yan, Yibing, primary, Watts, Ryan, primary, Bai, Shuang, primary, and Hegde, Priti S., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure Legend 1 from Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

Author

Ma, Wen Wee, primary, Messersmith, Wells A., primary, Dy, Grace K., primary, Weekes, Colin D., primary, Whitworth, Amy, primary, Ren, Chen, primary, Maniar, Manoj, primary, Wilhelm, Francois, primary, Eckhardt, S. Gail, primary, Adjei, Alex A., primary, and Jimeno, Antonio, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figures from Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer

Author

Parikh, Aparna R., primary, Van Seventer, Emily E., primary, Siravegna, Giulia, primary, Hartwig, Anna V., primary, Jaimovich, Ariel, primary, He, Yupeng, primary, Kanter, Katie, primary, Fish, Madeleine G., primary, Fosbenner, Kathryn D., primary, Miao, Benchun, primary, Phillips, Susannah, primary, Carmichael, John H., primary, Sharma, Nihaarika, primary, Jarnagin, Joy, primary, Baiev, Islam, primary, Shah, Yojan S., primary, Fetter, Isobel J., primary, Shahzade, Heather A., primary, Allen, Jill N., primary, Blaszkowsky, Lawrence S., primary, Clark, Jeffrey W., primary, Dubois, Jon S., primary, Franses, Joseph W., primary, Giantonio, Bruce J., primary, Goyal, Lipika, primary, Klempner, Samuel J., primary, Nipp, Ryan D., primary, Roeland, Eric J., primary, Ryan, David P., primary, Weekes, Colin D., primary, Wo, Jennifer Y., primary, Hong, Theodore S., primary, Bordeianou, Liliana, primary, Ferrone, Cristina R., primary, Qadan, Motaz, primary, Kunitake, Hiroko, primary, Berger, David, primary, Ricciardi, Rocco, primary, Cusack, James C., primary, Raymond, Victoria M., primary, Talasaz, AmirAli, primary, Boland, Genevieve M., primary, and Corcoran, Ryan B., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 3 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Author

Xin, Yan, primary, Li, Jessica, primary, Wu, Jenny, primary, Kinard, Rashell, primary, Weekes, Colin D., primary, Patnaik, Amita, primary, LoRusso, Patricia, primary, Brachmann, Rainer, primary, Tong, Raymond K., primary, Yan, Yibing, primary, Watts, Ryan, primary, Bai, Shuang, primary, and Hegde, Priti S., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 2 from Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Author

Xin, Yan, primary, Li, Jessica, primary, Wu, Jenny, primary, Kinard, Rashell, primary, Weekes, Colin D., primary, Patnaik, Amita, primary, LoRusso, Patricia, primary, Brachmann, Rainer, primary, Tong, Raymond K., primary, Yan, Yibing, primary, Watts, Ryan, primary, Bai, Shuang, primary, and Hegde, Priti S., primary

Published
2023
Full Text
View/download PDF

46. A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Author

Hong, Theodore S., primary, Yeap, Beow Y., additional, Horick, Nora K., additional, Wo, Jennifer Yon-Li, additional, Weekes, Colin D., additional, Allen, Jill N., additional, Qadan, Motaz, additional, Oberstein, Paul Eliezer, additional, Jain, Rakesh K., additional, Blaszkowsky, Lawrence Scott, additional, Wolpin, Brian M., additional, Laheru, Daniel A., additional, Messersmith, Wells A., additional, Ly, Leilana, additional, Drapek, Lorraine C., additional, Ting, David Tsai, additional, Burkhart, Richard A., additional, Fernandez-del Castillo, Carlos, additional, Kimmelman, Alec, additional, and Ryan, David P., additional

Published
2023
Full Text
View/download PDF

48. Phase Ib study testing neoadjuvant transforming growth factor (TGF)-β antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Author

Weekes, Colin D., primary, Ting, David Tsai, additional, Parikh, Aparna Raj, additional, Ittershagen, Stacie, additional, Fabre, Claire, additional, Cremasco, Viviana, additional, Ruddy, David, additional, Liss, Andrew, additional, O'Shea, Aileen, additional, Harisinghani, Mukesh, additional, Piquet, Michelle, additional, Chang, Jonathan, additional, Kwak, Eunice Lee, additional, and Ryan, David P., additional

Published
2023
Full Text
View/download PDF

49. Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.

Author

Vora, Kruti Bhagirath, primary, Ouyang, Ben, additional, Pappas, Leon, additional, Reynolds, Kerry Lynn, additional, Strickland, Matthew, additional, Allen, Jill N., additional, Weekes, Colin D., additional, Corcoran, Ryan Bruce, additional, Blaszkowsky, Lawrence Scott, additional, Ryan, David P., additional, Franses, Joseph Wang, additional, Chakrabarti, Sakti, additional, Klempner, Samuel J, additional, and Parikh, Aparna Raj, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results